AstraZeneca's durvalumab gets go-ahead on additional indication for biliary tract cancer
The company did not divulge the price of the product, but industry data pegs the price at 45,000-1.89 lakh for two available variants17-02-2023
17-02-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Has Received A No Objection For An Additional/Expanded Indication From The Central Drugs Standard Control Organisation, Directorate General Of Health Services, Government Of India, For Durvalumab (Imfinzi(tm)) 120 Mg/ 2.4 Ml And 500 Mg/ 10 Ml Solution For Infusion
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.14-02-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated February 2, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record.13-02-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed extract of the Newspaper Publication dated February 11, 2023 for the Financial Results for the quarter ended December 31, 2022 for your reference.13-02-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Friday, February 10, 2023 Pursuant To Regulations 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In continuation of our letter dated January 30, 2023, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e., Friday, February 10, 2023 inter alia considered and approved the Unaudited Financial Results for the quarter ended December 31, 2022 based on the recommendation of the Audit Committee. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors dated February 10, 2023 are enclosed herewith. The Meeting commenced at 2:30 P.M. and concluded at 5.00 P.M. (IST). Kindly take the above information on your records.10-02-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday, February 10, 2023 Pursuant To Regulations 30 And 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In continuation of our letter dated January 30, 2023, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e., Friday, February 10, 2023 inter alia considered and approved the Unaudited Financial Results for the quarter ended December 31, 2022 based on the recommendation of the Audit Committee. The said Unaudited Financial Results together with the Limited Review Report of the Statutory Auditors dated February 10, 2023 are enclosed herewith. The Meeting commenced at 2:30 P.M. and concluded at 5.00 P.M. (IST).10-02-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Friday, February 10, 2023
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 ,inter alia, to consider and approve This is to inform that the Meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Friday, February 10, 2023 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from December 16, 2022 to February 12, 2023 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record.30-01-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.30-01-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find the enclosed extract of the Newspaper Publication made on January 26, 2023 for the Notice of Postal Ballot for your reference.27-01-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are enclosing herewith the Postal Ballot Notice dated January 24, 2023 being sent to the Members of the Company to their registered email addresses, seeking approval of the Members for the Special Businesses as set out therein. The Notice is being sent to the Members whose names appear in the Register of Members/ Record of Depositories as on the cut-off date being Friday, January 20, 2023. The e-voting period commences on Thursday, January 26, 2023 (9:00 am IST) and ends on Saturday, February 25, 2023 (05:00 pm IST). The Company has engaged the services of National Securities Depository Limited for facilitating e-voting in a secured manner. The said Notice is also being made available on the website of the Company at www.astrazeneca.com/india. We request you to kindly take the same on record.25-01-2023